Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects

A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 4 Period Crossover Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of GW597901X in Asthmatic Subjects

This study is designed to look at the safety aspects and effects of repeat inhaled doses of GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive Pulmonary Disease(COPD).

Inclusion criteria:

• Subjects with mild to moderate stable asthma but no other lung problems.
• Male subjects or female subjects who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
• Non-Smokers.
• Subjects who show a measurable improvement in the function of their lungs after a single dose of salbutamol.

Exclusion criteria:

• Any significant illness.
• Subjects with heart problems.
• Subjects who have a cold or chest infection 2-4 weeks prior to the study or have life-threatening asthma.
• Subjects who take medication for their asthma, or other conditions, not compatible with this study.
• Subjects who are over sensitive to salbutamol or to ipratropium.